HALO — Halozyme Therapeutics, Inc.

Halozyme (HALO) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $354 million, up 22% year-over-year.
• Royalty Revenue: $236 million, a 52% increase year-over-year.
• Adjusted EBITDA: $248 million, reflecting a 35% growth compared to the prior year.
• GAAP Diluted EPS: $1.43; Non-GAAP Diluted EPS: $1.72, compared to $1.05 and $1.27 in Q3 2024, respectively.
• Cash Position: $702 million in cash and marketable securities, up from $596.1 million at year-end 2024.
• Net Debt-to-EBITDA Ratio: 0.9x at the end of Q3.

2. Strategic Updates and Business Highlights

• Product Performance: Continued strong sales from key products:
  • DARZALEX Subcutaneous: $3.7 billion in sales, 20% operational growth.
  • Phesgo: $2.3 billion in revenue, 54% year-over-year increase.
  • VYVGART Hytrulo: $1.13 billion in sales, 96% growth year-over-year.
• New Approvals:
  • DARZALEX received European approval for smoldering multiple myeloma.
  • VYVDURA with ENHANZE approved in Japan for self-injection.
• Acquisition of Elektrofi: Aimed at enhancing at-home administration of biologic therapies, expected to minimally impact net leverage at closing.
• Growth Catalysts: 13 out of 15 growth catalysts achieved year-to-date, including new product approvals and expanded indications.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Raised to $1.3 billion to $1.375 billion, reflecting 28% to 35% growth.
• Royalty Revenue Guidance: Expected to be $850 million to $880 million, a 49% to 54% increase.
• Adjusted EBITDA Guidance: Projected between $885 million and $935 million, representing 40% to 48% growth.
• Non-GAAP Diluted EPS Guidance: Expected to be $6.10 to $6.50, a 44% to 54% increase.

4. Bad News, Challenges, or Points of Concern

• Collaboration Revenues Decline: Collaboration revenues fell to $24 million from $48.4 million in the previous year, attributed to timing of milestones.
• Market Competition: Concerns regarding competition in the biologics market, particularly as key products approach the end of their patent life in the early 2030s.
• Dilution from Elektrofi Acquisition: Expected to be less than 5% dilutive to non-GAAP EPS over the medium term, with an anticipated $55 million increase in operating expenses for 2026.

5. Notable Q&A Insights

• Capital Allocation Strategy: Management emphasized a balanced approach between debt repayment and share repurchases, with a willingness to leverage up to 3x net debt for future acquisitions.
• New ENHANZE Deals: Confidence expressed in securing new ENHANZE agreements by year-end, with multiple discussions ongoing.
• Market Growth for OCREVUS: Uncertainty about whether new patients are switching from other therapies or are new to treatment; however, strong growth noted in community practices.
• Future Product Pipeline: Discussions on the potential for combining ENHANZE with Elektrofi’s Hypercon technology, but initial focus will remain on pursuing separate opportunities for each technology.

Overall, Halozyme reported a strong quarter with significant revenue growth driven by its core products, while also navigating challenges related to collaboration revenues and market competition. The company remains optimistic about future growth through strategic acquisitions and product development.